- cafead Oct 04, 2022 at 12:02: AM
via Alnylam has offered a closer look at the data that could support Onpattro’s quest to expand into a rare heart disease. While an approval looks likely, some industry watchers have raised fresh doubts about the drug’s commercial opportunity in its potential fight against Pfizer.
article source
article source